MVC develops new vaccines and affordable biosimilars to prevent regional infectious diseases. We aim to become one of the leading pharmaceutical companies for Taiwan and global communities.


Humanity, innovation, and quality are MVC’s core values. Based on the core values, we integrate biomedical technologies and strive to improve human health. We believe that every person, from infants to seniors, can be free from infectious diseases.

Medigen Vaccine Biologics Corporation (also known as MVC) is a biopharmaceutical company focusing on the development and production of vaccines and biologics. MVC has established a foothold in Taiwan and given priority to developing innovative pharmaceutical products for unmet medical needs. Meanwhile, MVC is dedicated to not only becoming the vaccine development and supply hub of the Asia-Pacific region but also protecting human health globally from the threats of various diseases.

  • 2017
    • MVC provided the CSR of EV71 vaccine Phase II study to TFDA
    • EV71 vaccine Phase III study was approved by TFDA
    • MVC signed a licensing agreement with Taiwan CDC for BCG vaccine and snake antivenoms.
    • The H7N9 Phase I/II study passed the GCP inspection.
  • 2016
    • The first EV71 vaccine protecting 2~6-month-old babies won Taiwan’s National Innovation Award.
    • MVC licensed in US NIH’s live attenuated dengue vaccine (TV003/TV005) and obtained the market rights to develop, make, sell and sublicense in 17 countries.
    • MVC inaugurated Taiwan’s first cell-based vaccine manufacturing plant.
    • MVC signed an agreement with US CDC to co-develop dengue VLP vaccine.
    • MVC signed an agreement with WHO/UCAB, mAbXience, Libbs and SPIMACO to form a consortium to co-develop biosimilar palivizumab against RSV.
  • 2015
    • MVC was granted National Innovation Award for the application of cell-based production technologies in mock-up vaccine manufacturing.
    • MVC listed on Taiwan OTC stock market (emerging stock market, stock code: 6547)
    • MVC entered the Phase I/II study for H7N9 vaccine.
  • 2014
    • MVC entered the Phase II study for EV71 vaccine.
    • MVC signed a licensing agreement with NHRI for H7N9 vaccine.
    • Groundbreaking ceremony of MVC vaccine plant was held at Hsinchu Biomedical Science Park.
  • 2013
    • MVC office settled at Neihu District, Taipei and initiated fund raising NT $1.2 billion for vaccine plant and R&D center at Zhubei City.
    • MVC signed the technology-transfer agreements with NHRI for EV71 vaccine technology and its Phase I clinical results.
  • 2012
    • Medigen Vaccinology Corp. (MVC) was founded.
    • MVC conducted the Phase I study for H5N1 vaccine.
  • 2009
    • “A-Team” cooperated with NHRI for cell-based H1N1 and H5N1 influenza vaccine development.
Quality Policy Statement

MVC is committed to delivering safe and effective products complied with regulatory requirements to consumers through continuous improvement of quality management system.